Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study

Bruno Brochet, Dawn Langdon, Eva Kubala Havrdova, Jeanette Lechner-Scott, Xavier Montalban, Francesco Patti, Fredrik Piehl, Alessandra Solari, Raymond Hupperts, Nektaria Alexandri, Annette Lehn, Andrzej Smyk, Krzysztof Selmaj,
Neurology and Therapy. 2026-06-01; :
DOI: 10.1007/s40120-026-00963-7

Brochet B(1), Langdon D(2), Havrdova EK(3), Lechner-Scott J(4)(5), Montalban X(6), Patti F(7), Piehl F(8), Solari A(9), Hupperts R(10), Alexandri N(11), Lehn A(11), Smyk A(11), Selmaj K(12)(13); CLARIFY-MS Investigators.

Author information:
(1)INSERM U1215, University of Bordeaux, Bordeaux, France.
.
(2)Department of Psychology, Royal Holloway, University of London, Egham,
Surrey, UK.
(3)First Medical Faculty, Department of Neurology and Center for Clinical
Neuroscience, Charles University, Prague, Czech Republic.
(4)University of Newcastle, Newcastle, NSW, Australia.
(5)Division of Neurology, John Hunter Hospital, Newcastle, NSW, Australia.
(6)Department of Neurology-Neuroimmunology Centre of Multiple Sclerosis of
Catalonia (Cemcat), University Hospital Vall d’Hebron, Barcelona, Spain.
(7)Department of Medical and Surgical Sciences and Advanced Technologies, GF
Ingrassia, University of Catania, and Azienda Ospedaliero Universitaria
Policlinico « G Rodolico »- San Marco, University of Catania, Catania, Italy.
(8)Department of Clinical Neuroscience, Karolinska Institutet, Stockholm,
Sweden.
(9)Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta,
Milan, Italy.
(10)Zuyderland Medisch Centrum Sittard, Maastricht University Medical Center,
Maastricht, The Netherlands.
(11)Merck Healthcare KGaA, Darmstadt, Germany.
(12)Center for Neurology, Lodz, Poland.
(13)Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland.